
McKesson ( MCK ) Surpasses Market Returns: Some Facts Worth Knowing
McKesson (MCK) reached $786 at the closing of the latest trading day, reflecting a +1.36% change compared to its last close.
Predicted Price is the pryogiTM prediction of where the price is going in next 3-4 quarters. There may be a revision of the predicted price every 3 months from the date of publication of the first predicted price of the stock. Price on Report Date is the price of the stock on the day prediction was published by pryogiTM. Current price shows the current price of the stock.
Margin of error shows range the price will end up in dollars either above or below the predicted price. Margin of error percentage shows the price will end up in percentage either above or below the predicted price.
Expected Returns from report date shows the returns (positive or negative) from published prediction date if you bought the stock on report date. Expected Returns from today shows the returns from today if you buy the stock today. A positive expected returns indicates a profit you will make, a negative expected return indicates a loss you will make if you buy the stock. There are different strategies to apply in the stock market for profit and loss, pryogiTM will publish such strategies in the future to help you.
PryogiTM meter shows you predicted price, price on the date this prediction was published(report date) and price of the stock today on a price scale. This indicates if the stock price is moving towards or away from the predicted price
PryogiTM performance chart shows actual movement of stock price from prediction published date(report date) and if the price is moving towards or away from predicted price
McKesson (MCK) reached $786 at the closing of the latest trading day, reflecting a +1.36% change compared to its last close.
West Pharma's Q3 numbers hinge on robust GLP-1 and biologics demand, but labor constraints, tariffs, and plant shutdowns could test its margin resilience.
Zacks spotlights UBS, Newmont, McKesson, and Cato, four companies showing strong performance across finance, gold mining, healthcare distribution, and retail.
UBS advances on solid earnings and integration progress, while Newmont and McKesson deliver strong gains through expansion and operational efficiency.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
In the closing of the recent trading day, McKesson (MCK) stood at $781.9, denoting a +1.61% move from the preceding trading day.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
McKesson ( NYSE:MCK ) has outperformed the market over the past 10 years by 2.25% on an annualized basis producing an average annual return of 14.73%. Currently, McKesson has a market capitalization of $95.25 billion.
McKesson (MCK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
MCK is transforming from a traditional distributor into a specialty-driven healthcare solutions leader, focusing on oncology, biopharma services and automation while preparing to separate its Medical-Surgical unit.
McKesson (MCK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
In the closing of the recent trading day, McKesson (MCK) stood at $738.06, denoting a -2.72% move from the preceding trading day.
BDX partners with Henry Ford Health to deploy BD Rowa Vmax robots, aiming to streamline 24/7 pharmacy access in Michigan.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
McKesson (MCK) reached $736.52 at the closing of the latest trading day, reflecting a -3.16% change compared to its last close.
McKesson ( NYSE: MCK ) has outperformed the market over the past 20 years by 5.87% on an annualized basis producing an average annual return of 14.69%. Currently, McKesson has a market capitalization of $91.61 billion.
Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The latest trading day saw McKesson (MCK) settling at $698.31, representing a +1.19% change from its previous close.
The latest trading day saw McKesson (MCK) settling at $719.8, representing a +1.92% change from its previous close.
Recently, Zacks.com users have been paying close attention to McKesson (MCK). This makes it worthwhile to examine what the stock has in store.
McKesson MCK has outperformed the market over the past 5 years by 21.84% on an annualized basis producing an average annual return of 35.72%. Currently, McKesson has a market capitalization of $86.44 billion.
McKesson MCK has outperformed the market over the past 20 years by 5.74% on an annualized basis producing an average annual return of 14.38%. Currently, McKesson has a market capitalization of $84.68 billion.
Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
COO's Q3 results may top estimates, powered by strong demand for MyDay lenses, Biofinity gains and surgical product resilience despite fertility softness.
CAH is set to buy Solaris Health for $2.4B, boosting urology presence with 750+ providers and expanding Specialty Alliance reach.
McKesson MCK has outperformed the market over the past 5 years by 20.42% on an annualized basis producing an average annual return of 34.18%. Currently, McKesson has a market capitalization of $84.15 billion.
Recently, Zacks.com users have been paying close attention to McKesson (MCK). This makes it worthwhile to examine what the stock has in store.
Despite tariff headwinds and softer elective procedure demand, McKesson, Cardinal Health, West Pharmaceutical Services, and The Cooper Companies are positioned for steady gains in the dental supplies space.
Here, we discuss four stocks from the Dental Supplies industry that are likely to generate wealth for investors amid tariff uncertainty. These are MCK, CAH, WST and COO.
WASHINGTON, Aug. 8, 2025 /PRNewswire/ -- Pharmacy Profiles, the trusted source for pharmacist identity and credentialing services, today announced a new agreement with McKesson Corporation to provide credential verification services for McKesson's Health Mart independent pharmacy network.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The continued solid uptake of Cardinal Health's products is expected to have driven fiscal fourth-quarter revenues despite an uncertain macroeconomic environment.
Everybody loves dividends, as they provide a passive income stream, limit drawdowns in other positions, and provide more than one way to profit from an investment.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
McKesson beats on Q1 earnings and raises FY26 EPS view, but shares slip as gross margin narrows and spin-off plans weigh on investors' sentiment.
McKesson (MCK) delivered earnings and revenue surprises of +0.36% and +1.82%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
BD's third-quarter fiscal 2025 results are likely to benefit from product launches across Medical and Interventional segments, which drive strong revenue potential.
SOLV's Q2 earnings are likely to test whether solid segment growth can offset tariff and ERP-related pressures.
MCK's Q1 results are expected to reflect strong prescription volume growth from GLP-1 demand, but lower margins may weigh on profitability.
COR benefits from strong specialty and GLP-1 demand, but Q3 results may face pressure from international weakness.
DIS, BJ, RL, and MCK stand out with strong interest coverage ratios, making them attractive picks in a volatile market.
XRAY's Imaging strength and SureSmile growth might have lifted Q2 performance, but Byte's drag and macro pressures likely clouded the top-line momentum.
McKesson MCK has outperformed the market over the past 5 years by 21.3% on an annualized basis producing an average annual return of 34.8%. Currently, McKesson has a market capitalization of $87.28 billion.
HIMS' second-quarter 2025 results are likely to benefit from subscriber momentum and digital care tools.
Evaluate the expected performance of McKesson (MCK) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.